Videos

Rafael Fonseca, MD, provides details on a patient case of transplant-ineligible multiple myeloma and reviews the selection of frontline triplet versus doublet therapy.

Lori A. Leslie, MD, discusses the impact that brexucabtagene autoleucel had on the treatment landscape for patients with relapsed or refractory mantle cell lymphoma.

Yuliya Mikheeva, MD, PhD, discusses the design of the phase 2 ANAPLAST-NEO study

Yelena Ginzburg, MD, discusses the prognosis and standard-of-care treatment in patients diagnosed with polycythemia vera.

Xiuning Le, MD, PhD, discusses counseling patients on the use of amivantamab-vmjw and mobocertinib and the sequencing of these drugs for patients with non–small cell lung cancer and an EGFR exon 20 insertion.

Lyudmila A. Bazhenova, MD, discusses targeted therapies for patients with BRAF-mutated non–small cell lung cancer.

In the third video of the series, Dr. Jyoti Malhotra from the Rutgers Cancer Institute of New Jersey shares expert insights on the benefits of using trilaciclib in clinical practice including considerations for chemotherapy treatment efficacy and patient quality of life. As of May 1, 2022, Dr. Malhotra is no longer with Rutgers Cancer Institute; she is now affiliated with City of Hope.

Before closing out her discussion on novel therapy for EGFR exon 20–positive NSCLC, Zofia Piotrowska, MD, shares her hopes for future developments in care.

Practical advice regarding the selection and management of amivantamab or mobocertinib in patients diagnosed with EGFR exon 20–positive NSCLC.

Comprehensive insight on the two novel, targeted agents approved for the management of EGFR exon 20–positive NSCLC following frontline therapy.

Expert oncologist Zofia Piotrowska, MD, reviews the case of a patient managed with frontline chemotherapy after receiving a diagnosis of stage 4 NSCLC.

Ron Bose, MD, PhD, discusses the challenge of drug resistance due to mutations for patients with HER2-positive breast cancer.

Valencia Thomas, MD, MHCM, discusses the current landscape regarding non-melanoma skin cancers.

Melhem Solh, MD, discusses how the standard of care for patients with myelodysplastic syndrome and acute myeloid leukemia with the tumor protein 53 gene mutation has changed over the past decade.

Anne Wooford, MD, provides background on her presentation around allogeneic stem cell transplant for the 2022 Transplantation & Cellular Therapy Meetings.

Thomas Hutson, MD, PharmD, discusses management strategies when confronting adverse events using combination therapies in treating patients with renal cell carcinoma.

Shannon N. Westin, MD, MPH, FACOG, discusses the endometrial cancer patient population enrolled in the phase 3 DUO-E trial.

Before closing out his discussion on novel therapy in EGFR exon 20 insertion–positive NSCLC, expert Joel Neal, MD, PhD, highlights ongoing clinical trials and the importance of testing.

Expert Joel Neal, MD, PhD, shares personal experience and highlights adverse event management strategies with amivantamab and mobocertinib in EGFR exon 20 insertion–positive NSCLC.

Carole Miller, MD, discusses notable factors which correlated with survival for patients with polycythemia vera in the REVEAL study.

The trial results of CHRYSALIS and EXCLAIM, which investigated amivantamab and mobocertinib, respectively, as second-line therapy for EGFR exon 20 insertion–positive NSCLC.

A comprehensive discussion on novel second-line agents amivantamab and mobocertinib, approved for EGFR exon 20 insertion–positive non–small cell lung cancer.

Expert perspective on the treatment armamentarium for EGFR exon 20 in non–small cell lung cancer.

Expert Joel Neal, MD, PhD, shares his perspectives on the frontline management of NSCLC and optimal strategies for molecular profiling in this setting.

A case of a 64-year-old man with non–small cell lung cancer, who tested positive for an EGFR exon 20 insertion mutation after progression on frontline therapy.

Bassel El-Rayes, MD, discusses how he approaches second-line therapy for patients with HER2-positive gastric cancer.

Dr John Mascarenhas looks to the future of myelofibrosis treatment and shares some ongoing clinical trials and potential treatments that excite him.

John Mascarenhas, MD, describes his personal experience with using pacritinib to treat patients with myelofibrosis and reviews the study design and outcomes for both the PERSIST-1 and PERSIST-2 trials.

Dr John Mascarenhas reviews the mechanism of action of pacritinib, a selective JAK2 inhibitor.

An expert describes the factors he considers when choosing a treatment for a patient with myelofibrosis, and how he judges treatment response.